Abstract
Conditional estimates provide a dynamic prediction of outcomes but to our knowledge there are no data on nonmuscle invasive bladder cancer. We assessed changes in conditional recurrence and progression rates after transurethral resection of the bladder and explored the prognostic impact of established factors and risk groups with time. We retrospectively analyzed data on 1,292 consecutive patients with newly diagnosed Ta/T1 bladder cancer who underwent transurethral resection of the bladder. Study end points were time to first recurrence and time to progression. The 2-year recurrence rate at baseline was 36%, which improved as a function of the time that patients were free of disease recurrence. After 6, 12, 24, 36 and 48 months the 2-year conditional recurrence rate improved to 31% (14% improvement vs baseline), 22% (39% improvement), 16% (56% improvement), 13% (64% improvement) and 11% (69% improvement), respectively. Comparably, conditional progression rates improved with increasing followup, although relative differences were less distinct. The prognostic impact of established factors and nonmuscle invasive bladder cancer risk groups progressively decreased with time and finally disappeared. However, bacillus Calmette-Guéri...Continue Reading
References
Jan 31, 2006·European Urology·Richard J SylvesterKarlheinz Kurth
Apr 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maryska L G Janssen-HeijnenJan-Willem W Coebergh
Jul 31, 2010·Advances in Urology·Ali A Al-Zahrani
Mar 2, 2011·Cancer·Rodolphe ThuretPierre I Karakiewicz
Dec 27, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Maxine SunPierre I Karakiewicz
Jul 4, 2012·International Journal of Cancer. Journal International Du Cancer·Freddie BrayJacques Ferlay
Aug 11, 2012·The Lancet Oncology·Lauren C HarshmanToni K Choueiri
Oct 10, 2012·BMC Cancer·Xue Qin YuDianne L O'Connell
Oct 23, 2012·The Journal of Urology·Cheryl T LeeThomas Bramley
May 30, 2013·BJU International·Marco BianchiMaxine Sun
Jun 27, 2013·BMC Cancer·Yuri ItoHideaki Tsukuma
Jul 6, 2013·European Urology·Marko BabjukUNKNOWN European Association of Urology
Aug 6, 2013·Urologic Oncology·Firas AbdollahRoberto Bertini
Aug 6, 2013·Cancer·Emily C ZaborKatherine S Panageas
Aug 29, 2013·British Journal of Cancer·E XylinasS F Shariat
Oct 22, 2013·European Urology·Guillaume PloussardWassim Kassouf
Jul 25, 2014·PharmacoEconomics·Christina YeungJoseph Lee
Aug 26, 2014·European Urology·Guillaume PloussardWassim Kassouf
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
Apr 11, 2015·World Journal of Urology·Ines A EdererTobias Klatte
Jun 21, 2015·European Urology·Richard J SylvesterMarek Babjuk
Aug 4, 2015·The Journal of Urology·Norm D SmithGary D Steinberg
Aug 27, 2015·The Journal of Urology·Akira YokomizoSeiji Naito
Oct 13, 2015·The Journal of Urology·Donald L Lamm
Citations
Jun 22, 2017·The Journal of Urology·Keisuke ShigetaMototsugu Oya
Oct 27, 2018·The Journal of Urology·Sam S Chang
Jul 11, 2019·Oncology Letters·Ilaria LuccaMichela De Martino
Jul 12, 2020·Annals of Surgical Oncology·Masayoshi KawakamiAkira Miyajima
Aug 18, 2020·BJU International·Yuki KohadaAkio Matsubara